3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
106
Carcinoma, Intraductal, Noninfiltrating
6
Neoplasms
4
Neoplasm Metastasis
3
Breast Neoplasms, Male
3
Breast Diseases
3
Breast Carcinoma In Situ
3
Triple Negative Breast Neoplasms
2
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Breast Cancer Metastatic
2
Sexual Dysfunction, Physiological
1
Seizures
1
Multiple Endocrine Neoplasia Type 1
1
Locoregional Recurrence
1
Lethal Congenital Contracture Syndrome 2
1
Inflammatory Breast Neoplasms
1
Hypogonadism
1
Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
1
HER2-positive Breast Cancer
1
HER2 Negative Breast Cancer
1
Granulosa Cell Ovarian Cancer
1
Fallopian Tube Neoplasms
1
Erectile Dysfunction
1
Epilepsy
1
Endometrial Stromal Tumors
1
ER+ Breast Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Neoplasm Female
1
Interventions
bicalutamide
4
pembrolizumab
1
nilutamide
1
exemestane
1
darolutamide
1
cabazitaxel
1
apalutamide
1
abemaciclib
1
Vorinostat
1
Triptorelin Pamoate
1
Tamoxifen
1
Letrozole
1
Histamine H2 Antagonists
1
Histamine Antagonists
1
Goserelin
1
Doxorubicin
1
Dasatinib
1
Cisplatin
1
CP protocol
1
Aromatase Inhibitors
1
Antiemetics
1
Anastrozole
1
Adrenal Cortex Hormones
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Bulbo-Spinal Atrophy, X-Linked
×
Anastrozole
×
Clear all
NCT02910050
2017-12-22
BETTER
Sun Yat-sen University
Phase 2
Unknown
58 enrolled